BRAF and cutaneous mastocytosis: ALM has a lower incidence of activating mutations in BRAF and PTEN, but a higher incidence of activating mutations or amplifications of wild-type KIT, a type of receptor tyrosine kinase, compared to SSM or nodular CM [19].